Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Michigan Retailers Free Rx Card Can Help Seniors
A free card from the Michigan Retailers Association can lift some of the weight of concern and worry for seniors buying expensive prescription drugs.
generic viagra online
Governor Rell: State Of Connecticut To Receive $3.75 Million Grant To Enhance Heath Care Access For At-Risk Mothers
Governor M. Jodi Rell announced that the State of Connecticut is receiving $3.75 million federal grant to expand access to health care in Hartford for low-income women nearing childbirth to ensure their newborns get a healthy start.
News of the day
ARIAD Announces Preliminary Results From Ongoing Clinical Trial Of Its Investigational, Bcr-Abl Inhibitor In Drug-Resistant Chronic Myeloid Leukemia
ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) announced preliminary clinical data from an ongoing Phase 1 clinical trial of its investigational, multi-targeted kinase inhibitor, AP24534, in patients with advanced hematological cancers. The study results provide initial clinical evidence of hematologic, cytogenetic and molecular anti-cancer activity of AP24534 in heavily pretreated patients with resistant and refractory chronic myeloid leukemia (CML), including those with the T315I mutant variant of the target protein, Bcr-Abl. An abstract describing these data is being submitted for presentation at a major hematology meeting to be held later this year.
Health Insurance

Genetically-Engineered MSCs Kill Metastatic Lung Cancer Cells In Mice

Researchers in London have demonstrated the ability of adult stem cells from bone marrow (mesenchymal stem cells, or MSCs) to deliver a cancer-killing protein to tumors. The genetically engineered stem cells are able to home to the cancer cells, both in culture and in mouse models, and deliver TNF-related apoptosis-inducing ligand (TRAIL), destroying the tumor cells while sparing normal cells. The research will be presented on Tuesday, May 19, at the American Thoracic Society"s 105th International Conference in San Diego. "Present oncological therapies are limited by host toxicity," said Michael Loebinger, M.D., M.A, who, along with S. M. Janes, M.D., Ph.D., conducted the research at the Centre for Respiratory Research at the University College of London. "They are also limited by cancer resistance and may not destroy cancer stem cells." With these experiments, the investigators combined two disparate areas of research that they believed held promise for treating cancer. Studies had shown that MSCs can be used as vectors to deliver anti-tumor therapy, while other studies found that TRAIL killed cancer cells, but not normal cells. For their experiments, Drs. Loebinger and Janes identified those cells likely to be resistant to therapies (cancer cells that have characteristics of stem cells) and found that they were just as likely to be destroyed as tumor cells by this novel therapy. In culture, the stem cells caused lung, squamous, breast and cervical cancer cells to die (all p


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009